These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 19453400)
1. Safety and immunogenicity of Sinovac's prototype pandemic influenza H5N1 vaccines: a review on clinical trials. Qiu YZ; Yin WD Influenza Other Respir Viruses; 2008 Nov; 2(6):237-42. PubMed ID: 19453400 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454 [TBL] [Abstract][Full Text] [Related]
4. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Leroux-Roels I; Borkowski A; Vanwolleghem T; Dramé M; Clement F; Hons E; Devaster JM; Leroux-Roels G Lancet; 2007 Aug; 370(9587):580-9. PubMed ID: 17707753 [TBL] [Abstract][Full Text] [Related]
5. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production. Dong J; Matsuoka Y; Maines TR; Swayne DE; O'Neill E; Davis CT; Van-Hoven N; Balish A; Yu HJ; Katz JM; Klimov A; Cox N; Li DX; Wang Y; Guo YJ; Yang WZ; Donis RO; Shu YL Influenza Other Respir Viruses; 2009 Nov; 3(6):287-95. PubMed ID: 19903211 [TBL] [Abstract][Full Text] [Related]
6. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828 [TBL] [Abstract][Full Text] [Related]
7. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. Carter NJ; Plosker GL BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial. Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093 [TBL] [Abstract][Full Text] [Related]
9. Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells. Legastelois I; Garcia-Sastre A; Palese P; Tumpey TM; Maines TR; Katz JM; Vogel FR; Moste C Influenza Other Respir Viruses; 2007 May; 1(3):95-104. PubMed ID: 19453414 [TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines. Chada KE; Forshee R; Golding H; Anderson S; Yang H Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200 [TBL] [Abstract][Full Text] [Related]
11. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164 [TBL] [Abstract][Full Text] [Related]
12. Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine). Gambaryan AS; Lomakina NF; Boravleva EY; Kropotkina EA; Mashin VV; Krasilnikov IV; Klimov AI; Rudenko LG Influenza Other Respir Viruses; 2012 May; 6(3):188-95. PubMed ID: 21951678 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). Rudenko L; Desheva J; Korovkin S; Mironov A; Rekstin A; Grigorieva E; Donina S; Gambaryan A; Katlinsky A Influenza Other Respir Viruses; 2008 Nov; 2(6):203-9. PubMed ID: 19453396 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398 [TBL] [Abstract][Full Text] [Related]
15. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine. Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. Ikeno D; Kimachi K; Kino Y; Harada S; Yoshida K; Tochihara S; Itamura S; Odagiri T; Tashiro M; Okada K; Miyazaki C; Ueda K Microbiol Immunol; 2010 Feb; 54(2):81-8. PubMed ID: 20377741 [TBL] [Abstract][Full Text] [Related]